OS Therapies Third Quarter 2026 Corporate Outlook
OS Therapies achieved full regulatory alignment with EMA, MHRA, and TGA for Conditional Marketing Authorisation, targeting early market access using 3-year overall survival data and biomarkers. The company plans to initiate a confirmatory Phase 3 study in Australia by the end of Q3 2026 and expects a pivotal FDA meeting to align on the Biologics License Application for Accelerated Approval.
Key figures
- Loc draw
- $1.6 million
- Loc amount
- $10 million
- Phase3 cost
- $1 million
- Phase3 start date
- end of the third quarter of 2026
- Tax credits expected
- $4.6 million
- Ema submission window
- September 30, 2026
- Tax credits outstanding
- $5.6 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.